BioNTech (Germany) Today
| 22UA Stock | EUR 114.70 1.30 1.15% |
Performance13 of 100
| Odds Of DistressLess than 9
|
BioNTech is trading at 114.70 as of the 29th of November 2024. This is a 1.15 percent increase since the beginning of the trading day. The stock's lowest day price was 114.0. BioNTech has less than a 9 % chance of experiencing financial distress in the next few years and had a good performance during the last 90 days. Equity ratings for BioNTech SE are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 30th of October 2024 and ending today, the 29th of November 2024. Click here to learn more.
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany. BIONTECH operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. The company has 242.68 M outstanding shares. More on BioNTech SE
Moving against BioNTech Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
BioNTech Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. BioNTech's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding BioNTech or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Biotechnology, Healthcare (View all Sectors) |
BioNTech SE (22UA) is traded on Frankfurt Exchange in Germany and employs 4,000 people. The company currently falls under 'Large-Cap' category with a current market capitalization of 30.49 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate BioNTech's market, we take the total number of its shares issued and multiply it by BioNTech's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. BioNTech SE operates under Healthcare sector and is part of Biotechnology industry. The entity has 242.68 M outstanding shares.
BioNTech SE has accumulated about 914.9 M in cash with 889.7 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.75.
Check BioNTech Probability Of Bankruptcy
Ownership AllocationBioNTech holds a total of 242.68 Million outstanding shares. BioNTech SE shows majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 64.0 percent of BioNTech SE outstanding shares that are owned by insiders signifies that they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check BioNTech Ownership Details
BioNTech SE Risk Profiles
Although BioNTech's alpha and beta are two of the key measurements used to evaluate BioNTech's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 2.62 | |||
| Semi Deviation | 2.6 | |||
| Standard Deviation | 3.98 | |||
| Variance | 15.84 |
BioNTech Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in BioNTech without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Performance Analysis Now
Performance AnalysisCheck effects of mean-variance optimization against your current asset allocation |
| All Next | Launch Module |
BioNTech Corporate Management
Elected by the shareholders, the BioNTech's board of directors comprises two types of representatives: BioNTech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BioNTech. The board's role is to monitor BioNTech's management team and ensure that shareholders' interests are well served. BioNTech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BioNTech's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jens Holstein | CFO Board | Profile | |
| Sylke Maas | VP Strategy | Profile | |
| James Ryan | Sr Counsel | Profile | |
| Michael Boehler | MD Communications | Profile | |
| Ryan Richardson | MD Officer | Profile | |
| Sierk Poetting | COO MD | Profile |
Additional Information and Resources on Investing in BioNTech Stock
When determining whether BioNTech SE offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BioNTech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biontech Se Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biontech Se Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNTech SE. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.